What are the dosing guidelines, contraindications, precautions, and common adverse effects of bupropion for treating depression and for smoking cessation?

Bupropion: Clinical Guidelines for Depression and Smoking Cessation

Bupropion is an effective medication for both major depressive disorder and smoking cessation, with a standard dosing regimen of 150 mg once daily for 3 days, then 150 mg twice daily (maximum 300 mg/day), but it is absolutely contraindicated in patients with seizure disorders, eating disorders, or those taking MAO inhibitors. 1, 2

Dosing Guidelines

For Smoking Cessation

• Initiate 1-2 weeks prior to target quit date 1
• Days 1-3: 150 mg orally once daily
• Day 4 through 7-12 weeks: 150 mg orally twice daily (if tolerated)
• Maximum dose: 300 mg per day
• Duration: 7-12 weeks standard; may extend to 6 months-1 year for continued cessation 1

For Major Depressive Disorder

• Starting dose: 150 mg once daily 2
• After 4 days: May increase to 300 mg once daily (usual target dose)
• Maximum dose: 450 mg per day (for depression only, not smoking cessation) 2

Dose Adjustments

• Moderate to severe hepatic impairment: 150 mg every other day 2
• Mild hepatic impairment: Consider reducing dose and/or frequency 2
• Renal impairment: Consider reducing dose and/or frequency 2

Absolute Contraindications

Do not prescribe bupropion if the patient has: 1, 2

• Seizure disorder (current or history)
• Seizure risk factors: stroke, brain metastases, traumatic brain injury
• Current or prior bulimia or anorexia nervosa
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
• MAO inhibitor use (within 14 days)
• Concurrent tamoxifen use (increased risk of hypertensive reactions) 1
• Closed-angle glaucoma 1
• Known hypersensitivity to bupropion 2

Critical Precautions and Monitoring

Black Box Warning: Suicidality

Monitor all patients closely for worsening depression, suicidal thoughts, and behavioral changes, especially in the first 1-2 weeks of treatment. 2 This risk is highest in patients under 24 years of age. However, the EAGLES trial (n=8,058) found no significant increase in neuropsychiatric adverse events with bupropion compared to placebo in patients with or without psychiatric disorders 1.

Neuropsychiatric Monitoring

Watch for and instruct patients to immediately report: 2

• Changes in mood (depression, mania)
• Psychosis, hallucinations, paranoia, delusions
• Aggression, hostility, agitation
• Anxiety, panic attacks
• Suicidal ideation or attempts

Cardiovascular Monitoring

• Monitor blood pressure before and periodically during treatment 2
• Bupropion can increase blood pressure; avoid in uncontrolled hypertension 3
• No significant increase in major cardiovascular events has been demonstrated 4

Seizure Risk Management

The seizure risk is approximately 0.1% (1 in 1,000) at the recommended 300 mg/day dose. 5, 6 To minimize risk:

• Gradually titrate dose
• Do not exceed 300 mg/day for smoking cessation
• Screen carefully for seizure risk factors
• Discontinue immediately if seizure occurs 2

Common Adverse Effects

Most common (≥5% and ≥2× placebo): 2

• Dry mouth
• Insomnia (most common; dose late in day to minimize) 3
• Nausea
• Headache
• Dizziness
• Agitation/anxiety
• Tremor
• Sweating

Important: Insomnia and anxiety are also nicotine withdrawal symptoms, making attribution challenging 6. These effects are generally transient and resolve within 4-5 days without intervention 7, 6.

Serious but Rare Adverse Effects

• Seizures: ~0.1% at 300 mg/day 5, 8
• Severe hypersensitivity reactions: ~0.1% (including angioedema, anaphylaxis) 8
• Angle-closure glaucoma in patients with untreated anatomically narrow angles 2

Discontinuation Rate

Only 6-12% of patients discontinue due to adverse events in clinical trials, indicating good overall tolerability 6. However, bupropion does increase treatment discontinuation compared to placebo (RR 1.37) 9.

Efficacy Data

Smoking Cessation

Bupropion significantly increases long-term smoking cessation rates (RR 1.64,95% CI 1.52-1.77) 9. At one year:

• Bupropion 300 mg: 23.1% abstinence
• Placebo: 12.4% abstinence 10

Bupropion is less effective than varenicline (RR 0.71,95% CI 0.64-0.79) but equivalent to nicotine replacement therapy (RR 0.99) 9.

Depression

Bupropion produces similar remission rates to SSRIs with a median time to relapse of 44 weeks 7. Response typically occurs within 2 weeks, with full efficacy at 4 weeks 7.

Drug Interactions

Critical Interactions

• CYP2D6 substrates: Bupropion inhibits CYP2D6; consider dose reduction of antidepressants (venlafaxine, SSRIs, TCAs), antipsychotics (haloperidol, risperidone), beta-blockers (metoprolol), and Type 1C antiarrhythmics (propafenone, flecainide) 2
• CYP2B6 inducers: May require bupropion dose increase (ritonavir, efavirenz, carbamazepine, phenobarbital, phenytoin) 2
• Drugs lowering seizure threshold: Use with extreme caution 2
• Dopaminergic drugs (levodopa, amantadine): Risk of CNS toxicity 2

Opioid Considerations

For naltrexone-bupropion combination (Contrave): Discontinue before procedures requiring opioids; naltrexone component blocks opioid efficacy 3.

Special Populations

Patients with Depression

Bupropion is particularly appropriate for patients with comorbid depression and smoking, as it treats both conditions simultaneously 7, 11. It is the only antidepressant with no serotonergic activity, making it useful when SSRIs cause sexual dysfunction 12, 7.

Weight Management

Bupropion reduces cessation-related weight gain. Mean weight gain at end of treatment was inversely dose-related: 2.9 kg (placebo) vs 1.5 kg (300 mg bupropion) 10. The naltrexone-bupropion combination is FDA-approved for obesity management 3.

Patients with Psychiatric History

The EAGLES trial demonstrated that bupropion does not significantly increase neuropsychiatric adverse events even in patients with diagnosed psychiatric disorders 1. However, maintain heightened monitoring.

Clinical Pearls

• Combination therapy: Bupropion + NRT shows trends toward improved efficacy but evidence is insufficient to definitively recommend (RR 1.19,95% CI 0.94-1.51) 9
• False-positive drug screens: Bupropion can cause false-positive urine tests for amphetamines 2
• Timing of second dose: Avoid late-day dosing to minimize insomnia 3
• Treatment failure: If patient has not lost 5% body weight (for obesity indication) or achieved abstinence after 12 weeks on maintenance dose, consider switching therapies 3
• Nortriptyline alternative: If bupropion is contraindicated, nortriptyline also aids smoking cessation (RR 2.03 vs placebo) but has more side effects 9